Our group has previously reported that ipilimumab therapy can augment humoral and cellular immune responses against different melanoma-associated tumor antigens, including gp100 and NY-ESO-1, a prototypical cancer-testis antigen, whose expression is restricted to the testes and certain malignant tissues, including melanoma [34,36]. This evidence concerns the gene PMEL and cancer.